查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587292

組合抗體療法市場：按類型、適應症、給藥途徑、分銷管道、最終用途分類 - 全球預測 2025-2030

Combination Antibody Therapy Market by Type (Antibody-Drug Conjugates, Bispecific Antibodies, Chemotherapy-Monoclonal Antibodies), Indication (Cancer, HIV), Route of Administration, Distribution Channel, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年聯合抗體治療市值為2093.7億美元，預計到2024年將達到2315.5億美元，複合年成長率為9.30%，到2030年將達到3901.8億美元。

聯合抗體療法是指使用兩種或多種針對不同抗原或抗原表位的單株抗體來治療各種疾病，特別是癌症、自體免疫疾病和感染疾病。這種方法旨在提高治療效果，克服抗藥性，並對病理目標提供多方面的攻擊。對組合抗體療法的需求源自於難以用單一藥物治療的複雜疾病的日益普及。聯合治療可以增強協同效應，減少抗藥性，提高緩解率，從而滿足重要的未滿足的醫療需求。應用範圍從腫瘤學到腫瘤生長、類風濕性關節炎等慢性疾病以及 COVID-19 等感染疾病的多種途徑。最終用途範圍包括從事開發先進治療解決方案的醫院、診所和研究機構。

主要市場統計
基準年[2023] 2093.7億美元
預測年份 [2024] 2315.5億美元
預測年份 [2030] 3901.8億美元
複合年成長率（%） 9.30%

聯合抗體治療市場的成長主要是由生物技術的進步和製藥行業研發支出的增加以及慢性病和文明病盛行率的上升所推動的。治療抗體管道的擴大和醫療保健支出的增加進一步推動了市場的發展。最近，個人化醫療和精準治療的潛力已經成為一個機會。利用全面的患者資料分析來開發客製化的聯合治療可以顯著改善治療結果。對公司的建議包括投資夥伴關係和協作研究以加速創新，以及部署技術以簡化研究方法。

儘管潛力巨大，但聯合抗體治療市場面臨開發成本高、監管挑戰、生產過程複雜以及免疫副作用風險等限制。值得探索的創新領域包括使用人工智慧來最佳化抗體選擇和組合、新穎的遞送機制以及預測治療反應的預測模型。市場的特點是技術進步快、競爭激烈，需要靈活的策略來確保競爭優勢。對新型抗體和免疫系統相互作用的持續研究對於維持這個充滿活力和不斷發展的領域的業務成長至關重要。

市場動態：揭示快速發展的組合抗體療法市場的關鍵市場洞察

供需的動態交互作用正在改變聯合抗體治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症患者數量增加
    • 改善治療和患者治療效果的需求日益成長
    • 用於抗藥性管理
  • 市場限制因素
    • 聯合抗體療法的高成本和複雜性
  • 市場機會
    • 聯合抗體療法的持續研究和臨床測試
    • 個人化醫療方法的新用途
  • 市場問題
    • 與聯合抗體療法相關的副作用

波特五力：駕馭聯合抗體治療市場的策略工具

波特的五力框架是了解組合抗體療法市場競爭格局的關鍵工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解聯合抗體治療市場的外部影響

外部宏觀環境因素在塑造聯合抗體治療市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解聯合抗體治療市場的競爭格局

組合抗體療法市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣組合抗體治療市場供應商績效評估

FPNV定位矩陣是評估合併抗體治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：在聯合抗體療法市場中製定成功之路

聯合抗體治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的癌症患者數量正在增加。
      • 改善治療和患者治療效果的需求日益增加
      • 用於抗藥性管理
    • 抑制因素
      • 聯合抗體療法的高成本和複雜性
    • 機會
      • 聯合抗體療法的持續研究和臨床測試
      • 個人化醫療方法的新用途
    • 任務
      • 與聯合抗體療法相關的不良反應
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 組合抗體治療市場：依類型

  • 介紹
  • 抗體藥物偶聯物
  • 雙特異性抗體
  • 化療單株抗體

第7章 合併抗體治療市場：依適應症分類

  • 介紹
  • 癌症
    • 血癌
    • 乳癌
    • 大腸直腸癌
    • 肺癌
  • HIV

第8章 組合抗體治療市場：依給藥途徑

  • 介紹
  • 口服
  • 胃腸外的

第9章組合抗體治療市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章組合抗體治療市場：依最終用途

  • 介紹
  • 居家醫療
  • 醫院
  • 專業中心

第11章美洲聯合抗體治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太聯合抗體治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的聯合抗體治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • Argenx SE
  • AstraZeneca PLC
  • Atreca, Inc.
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • CStone Pharmaceuticals
  • Eli Lilly and Company
  • Five Prime Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • I-Mab Biopharma Co., Ltd.
  • IGM Biosciences, Inc.
  • Incyte Corporation
  • Janssen Pharmaceuticals, Inc. by Johnson & Johnson Service Inc.
  • Jazz Pharmaceuticals plc
  • Kyowa Kirin Co., Ltd.
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • MorphoSys AG
  • NBE-Therapeutics AG
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Trillium Therapeutics Inc.
  • Xencor, Inc.
  • Zymeworks Inc.
Product Code: MRR-DD0700E81E99

The Combination Antibody Therapy Market was valued at USD 209.37 billion in 2023, expected to reach USD 231.55 billion in 2024, and is projected to grow at a CAGR of 9.30%, to USD 390.18 billion by 2030.

Combination antibody therapy refers to the use of two or more monoclonal antibodies to target different antigens or epitopes to treat various diseases, particularly cancer, autoimmune, and infectious diseases. This approach aims to enhance therapeutic efficacy, overcome resistance, and provide a multifaceted attack on pathological targets. The necessity for combination antibody therapy arises from the increasing prevalence of complex diseases that challenge single-agent treatments. Combination therapy allows for enhanced synergistic effects, reduced drug resistance, and improved response rates, thereby meeting critical unmet medical needs. Its application spans oncology, where it is used to target multiple pathways involved in tumor growth, as well as in chronic diseases like rheumatoid arthritis and infectious diseases like COVID-19. The end-use scope includes hospitals, clinics, and research institutes engaged in developing advanced therapeutic solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 209.37 billion
Estimated Year [2024] USD 231.55 billion
Forecast Year [2030] USD 390.18 billion
CAGR (%) 9.30%

The growth of the combination antibody therapy market is primarily driven by advancements in biotechnology and increased R&D spending in the pharmaceutical sector, coupled with a rising prevalence of chronic and lifestyle-associated diseases. An expanding pipeline of therapeutic antibodies and increasing healthcare expenditure further fuel the market. Lately, the potential for personalized medicine and precision treatment has emerged as an opportunity; leveraging comprehensive patient data analytics to develop tailored combination therapies could significantly enhance outcomes. Recommendations for companies include investing in partnerships and collaborations to accelerate innovation and adopting technology to streamline research processes.

Despite its promising potential, the combination antibody therapy market faces limitations such as high development costs, regulatory challenges, complex production processes, and the risk of adverse immunological responses. Innovative areas to explore include the use of artificial intelligence to optimize antibody selection and combination, novel delivery mechanisms, and predictive modeling to anticipate therapeutic responses. The market is characterized by rapid technological advancements and intense competition, necessitating agile strategies to secure a competitive edge. Continued research into novel antibodies and immune system interactions will be crucial for sustaining business growth in this dynamic and evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Combination Antibody Therapy Market

The Combination Antibody Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising number of cancer cases worldwide
    • Growing need to enhance treatment and patient outcomes
    • Utilization for drug resistance management
  • Market Restraints
    • High cost and complexity of combination antibody therapy
  • Market Opportunities
    • Ongoing research and clinical trials for combination antibody therapy
    • Emerging use of personalized medicine approach
  • Market Challenges
    • Adverse effects associated with combination antibody therapy

Porter's Five Forces: A Strategic Tool for Navigating the Combination Antibody Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Combination Antibody Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Combination Antibody Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Combination Antibody Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Combination Antibody Therapy Market

A detailed market share analysis in the Combination Antibody Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Combination Antibody Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Combination Antibody Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Combination Antibody Therapy Market

A strategic analysis of the Combination Antibody Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Combination Antibody Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Argenx SE, AstraZeneca PLC, Atreca, Inc., Bayer AG, BeiGene, Ltd., Biogen Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, CStone Pharmaceuticals, Eli Lilly and Company, Five Prime Therapeutics, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, I-Mab Biopharma Co., Ltd., IGM Biosciences, Inc., Incyte Corporation, Janssen Pharmaceuticals, Inc. by Johnson & Johnson Service Inc., Jazz Pharmaceuticals plc, Kyowa Kirin Co., Ltd., MacroGenics, Inc., Merck & Co., Inc., MorphoSys AG, NBE-Therapeutics AG, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, Trillium Therapeutics Inc., Xencor, Inc., and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Combination Antibody Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Antibody-Drug Conjugates, Bispecific Antibodies, and Chemotherapy-Monoclonal Antibodies.
  • Based on Indication, market is studied across Cancer and HIV. The Cancer is further studied across Blood Cancer, Breast Cancer, Colorectal Cancer, and Lung Cancer.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End-Use, market is studied across Homecare, Hospitals, and Specialty Centres.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising number of cancer cases worldwide
      • 5.1.1.2. Growing need to enhance treatment and patient outcomes
      • 5.1.1.3. Utilization for drug resistance management
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and complexity of combination antibody therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and clinical trials for combination antibody therapy
      • 5.1.3.2. Emerging use of personalized medicine approach
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with combination antibody therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Combination Antibody Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Antibody-Drug Conjugates
  • 6.3. Bispecific Antibodies
  • 6.4. Chemotherapy-Monoclonal Antibodies

7. Combination Antibody Therapy Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
    • 7.2.1. Blood Cancer
    • 7.2.2. Breast Cancer
    • 7.2.3. Colorectal Cancer
    • 7.2.4. Lung Cancer
  • 7.3. HIV

8. Combination Antibody Therapy Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Combination Antibody Therapy Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Combination Antibody Therapy Market, by End-Use

  • 10.1. Introduction
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Centres

11. Americas Combination Antibody Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Combination Antibody Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Combination Antibody Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Argenx SE
  • 4. AstraZeneca PLC
  • 5. Atreca, Inc.
  • 6. Bayer AG
  • 7. BeiGene, Ltd.
  • 8. Biogen Inc.
  • 9. BioNTech SE
  • 10. Boehringer Ingelheim International GmbH
  • 11. Bristol Myers Squibb Company
  • 12. CStone Pharmaceuticals
  • 13. Eli Lilly and Company
  • 14. Five Prime Therapeutics, Inc.
  • 15. Gilead Sciences, Inc.
  • 16. GlaxoSmithKline plc
  • 17. I-Mab Biopharma Co., Ltd.
  • 18. IGM Biosciences, Inc.
  • 19. Incyte Corporation
  • 20. Janssen Pharmaceuticals, Inc. by Johnson & Johnson Service Inc.
  • 21. Jazz Pharmaceuticals plc
  • 22. Kyowa Kirin Co., Ltd.
  • 23. MacroGenics, Inc.
  • 24. Merck & Co., Inc.
  • 25. MorphoSys AG
  • 26. NBE-Therapeutics AG
  • 27. Novartis AG
  • 28. Pfizer Inc.
  • 29. Regeneron Pharmaceuticals, Inc.
  • 30. Roche Holding AG
  • 31. Sanofi S.A.
  • 32. Sutro Biopharma, Inc.
  • 33. Takeda Pharmaceutical Company Limited
  • 34. Trillium Therapeutics Inc.
  • 35. Xencor, Inc.
  • 36. Zymeworks Inc.

LIST OF FIGURES

  • FIGURE 1. COMBINATION ANTIBODY THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. COMBINATION ANTIBODY THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. COMBINATION ANTIBODY THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. COMBINATION ANTIBODY THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COMBINATION ANTIBODY THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COMBINATION ANTIBODY THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CHEMOTHERAPY-MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 280. COMBINATION ANTIBODY THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 281. COMBINATION ANTIBODY THERAPY MARKET, FPNV POSITIONING MATRIX, 2023